
Akeso Says Its Lung Cancer Drug Beat Pembrolizumab on Survival, but Released No Numbers
The Hong Kong-listed drug developer Akeso said on Sept. 2 that its lung-cancer antibody ivonescimab met the overall-survival endpoint of a Phase III trial that tested it against pembrolizumab, and…










